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Background
Long term maintenance with NRTI-sparing regimens
may be preferable for patients with NRTI toxicities, and
may offer potential cost savings. Dual ART with once
daily darunavir/r and etravirine may be preferable to
previous PI/r/NNRTI combinations due to its theoretical
higher genetic barrier to resistance and good PK profile.
We looked at the use of this regimen within our HIV
cohort.
Methods
Patients prescribed dual ART with darunavir/ritonavir
800mg/100mg QD with etravirine 400mg/day (DRV/r/
ETR) until January 2010 were identified by our virtual
clinic database. Reason for switch, HIV resistance, viral
outcomes were identified.
Results
21 patients were switched to DRV/r/ETR with median
time on regimen of 51.5 weeks (IQR 33-69 wks). 85%
(18/21) where given ETR 400mg QD. 62% (13/21)
switched from dual PI/r regimens, 10 combined with efa-
virenz or nevirapine. 28% (6/21) switched from conven-
tional cART (2 NRTI + PI/r or NNRTI). Patients had a
median exposure to 9 ARV drugs prior to switch (IQR 4-
11), with 90% (19/21) having previous NNRTI exposure,
7 of which had CNS toxicity with efavirenz. At switch,
57% (12/21) had no previous resistance, 19% (4/21) NRTI
mutations only, and 19% (4/21) had NNRTI mutations
(K103N (2), Y181C combined with NRTI K65R, M184V
mutations (1), prior NNRTI failure (2)). 90% (19/21) had
VL<50cps/ml at switch, with 95% (20/21) achieving/
maintaining VL<50cps/ml on regimen. Four patients
discontinued the regimen, 2 switching to darunavir/r
monotherapy, one switching to kivexa/darunavir/r due to
non-adherence, and one switching back to previous regi-
men after 4 weeks. One patient was lost to follow up.
Median virological follow of patients remaining on ther-
apy was up 40.8 wks (IQR 32-58 wks). Median CD4
change for the 17/21 who remained on therapy was +101
cells/mm
3 (IQR -50-138) with median 39 wks follow up
(IQR 31-58 wks). Indications for switch were desire for
simplification (9) (typically from dual PI), and need for
NRTI-sparing regimen (12), including previous renal
toxicity with tenofovir (4), lipoatrophy (7), peripheral
neuropathy (1) and lactic acidosis (2).
Conclusions
For patients with VL<50cps/ml, simplification to dual
therapy with darunavir/r 800/100mg QD plus etravirine
400mg QD maintains viral suppression and immune
reconstitution.
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